Get a proposal

Ophthalmology · Clinical trials

Diabetic Retinopathy Clinical Trials

Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.

Indication overview

About diabetic retinopathy — and why its trials are hard

Diabetic retinopathy (DR) is a progressive microvascular complication of diabetes and a leading cause of vision loss in working-age adults. It ranges from non-proliferative disease (microaneurysms, haemorrhages, capillary non-perfusion) to sight-threatening proliferative DR (PDR) with neovascularisation, vitreous haemorrhage and tractional detachment. For decades panretinal photocoagulation (PRP) was the standard for PDR, ablating ischaemic retina to regress neovascularisation. The landmark DRCR.net Protocol S showed intravitreal ranibizumab was non-inferior to PRP for visual acuity at two years while better preserving peripheral field and reducing vitrectomy. Anti-VEGF agents (aflibercept, ranibizumab) are now approved to improve DR severity, measured on the Diabetic Retinopathy Severity Scale (DRSS). PANORAMA and Protocol W tested proactive aflibercept in non-proliferative disease, showing robust DRSS improvement and fewer vision-threatening complications, though Protocol W found no visual-acuity benefit from prophylaxis. Regular screening, glycaemic and blood-pressure control remain foundational, with pharmacotherapy reserved for advanced or high-risk eyes.

Indication
Diabetic Retinopathy
ICD-10-CM
E11.319 — Type 2 diabetes with retinopathy

Approved therapies & pivotal evidence

What's been approved — and by how much it moved the endpoint

Drug (brand)ApprovedSettingPivotal trialPrimary endpointMagnitude of benefit
aflibercept (Eylea)2019Diabetic retinopathy (with or without DME)PANORAMA / DRCR.net Protocol S≥2-step improvement in DRSS scorePANORAMA: ~65% of aflibercept eyes achieved ≥2-step DRSS improvement at week 52 vs ~15% sham
ranibizumab (Lucentis)2017Diabetic retinopathyDRCR.net Protocol S / RISE and RIDEVisual acuity and DRSS; non-inferiority vs panretinal photocoagulationProtocol S: ranibizumab non-inferior to PRP for BCVA at 2 years (~+2.8 letters), with less peripheral field loss and fewer vitrectomies
aflibercept 8 mg (Eylea HD)2023Diabetic retinopathy (extended dosing)PHOTON (label extension)DRSS improvement / maintained control at extended intervalsHigh-dose aflibercept maintained retinopathy control at dosing intervals up to every 12–16 weeks

Where trials have failed

Drugs that missed their endpoint — and what contributed

The most instructive lessons in diabetic retinopathy development come from programmes that failed the endpoint that mattered.

Drug / trialEndpoint outcomeWhat contributed
ruboxistaurin (PKC-beta inhibitor) — PKC-DRS2Reduced sustained moderate visual loss vs placebo, but FDA issued a non-approvable/approvable letter requiring an additional confirmatory trial; never approved for DRSingle pivotal trial insufficient; modest effect on a secondary-type visual endpoint rather than DR progression; program ultimately discontinued
aflibercept (prophylactic, non-proliferative DR) — DRCR.net Protocol WReduced progression to PDR and centre-involved DME but showed no visual-acuity benefit vs sham at 4 yearsUntreated eyes that developed complications were rescued and caught up in vision, undermining the rationale for proactive anti-VEGF in eyes with good baseline acuity

Choosing the right endpoint

Primary endpoints that matter in diabetic retinopathy trials

  • DRSS ≥2-step improvement — Regulatory endpoint for DR severity; two or more steps on the ETDRS Diabetic Retinopathy Severity Scale reflects meaningful anatomical regression
  • BCVA (ETDRS letters) — Best-corrected visual acuity change; core functional outcome, though many NPDR eyes start with good vision limiting measurable gains
  • Progression to PDR / vision-threatening complications — Rate of developing proliferative disease, vitreous haemorrhage or centre-involved DME; used in PANORAMA and Protocol W
  • Peripheral visual field / vitrectomy rate — Safety and quality-of-life measures distinguishing anti-VEGF from panretinal photocoagulation

How iNGENū runs diabetic retinopathy trials

Physician-led design, built for FDA submission

Endpoint & biomarker strategy

Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.

FDA-ready data

Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.

Faster, lower-cost delivery

~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.

Planning a diabetic retinopathy trial?
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Request a proposal

Frequently asked questions

Diabetic Retinopathy clinical trials — FAQs

Can anti-VEGF injections replace laser for proliferative DR?
Protocol S showed ranibizumab is non-inferior to panretinal photocoagulation for visual acuity at two years with better peripheral field preservation, so anti-VEGF is a valid alternative, but laser remains valuable for patients who cannot adhere to frequent injections.
Should non-proliferative DR without oedema be treated proactively?
PANORAMA showed strong DRSS improvement, but Protocol W found no visual-acuity advantage over observation at four years, so proactive injection is not routinely recommended for eyes with good vision.
What is the DRSS and why does it matter?
The Diabetic Retinopathy Severity Scale grades retinopathy severity; a two-step improvement is the FDA-recognised anatomical endpoint used to approve anti-VEGF agents for diabetic retinopathy.

Ready to discuss your diabetic retinopathy trial?

Talk to our physician-led team about an FDA-ready, cost-efficient trial design.

Request a proposal